Vericel to Present at Multiple Upcoming Investor Conferences
September 09 2020 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced presentations at multiple upcoming investor conferences.
- The H.C. Wainwright 22nd Annual Global
Investment Conference on Tuesday, September 15th at 10am EST
- The 2020 Cantor Global Healthcare Conference on Wednesday,
September 16th at 4:00pm EST
- The Oppenheimer Fall Healthcare Summit on Monday, September
21st at 3:20pm EST
A live webcast of the presentations will be available on the
Investor Relations section of the Vericel Corporation website at:
http://investors.vcel.com.
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company’s website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2020 Vericel
Corporation. All rights reserved.
Investor Contacts:Lee SternSolebury
Troutlstern@soleburytrout.com+1 646-378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024